BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Y, Shu D, Shen M, Wu Q, Peng Y, Liu L, Tang Z, Gao S, Wang Y, Liu S, Cui D. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/9412119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Lv X, Wu J, Wei H, Liu S, Zou C, Song J, Li X, Ai Y. Identification and Validation of a Four-Gene Prognostic Signature Based on PPAR Signaling Pathway for Oral Squamous Cell Carcinoma.. [DOI: 10.21203/rs.3.rs-2560274/v1] [Reference Citation Analysis]
2 Pan Y, Zhang Q, Zhang H, Kong F. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Funct Integr Genomics 2023;23:38. [PMID: 36640225 DOI: 10.1007/s10142-023-00963-y] [Reference Citation Analysis]
3 Cui Y, Huang T, Zhang Z, Yang Z, Hao F, Yuan T, Zhou Z. The potential effect of BMSCs with miR-27a in improving steroid-induced osteonecrosis of the femoral head. Sci Rep 2022;12:21051. [PMID: 36473889 DOI: 10.1038/s41598-022-25407-8] [Reference Citation Analysis]
4 Xu Y, Shen M, Peng Y, Liu L, Tang L, Yang T, Pu D, Tan W, Zhang W, Liu S, Xu Y. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer. BioMed Research International 2022;2022:1-28. [DOI: 10.1155/2022/4632453] [Reference Citation Analysis]
5 Xu Y, Jin Y, Gao S, Wang Y, Qu C, Wu Y, Ding N, Dai Y, Jiang L, Liu S, Pan J. Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast Cancer. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/7204415] [Reference Citation Analysis]